Literature DB >> 19531457

Embryonal rhabdomyosarcoma of the uterine cervix.

Georgios V Koukourakis1, Vassilios Kouloulias, Georgios Zacharias, Georgios Maravelis, Christos Papadimitriou, Kaliopi Platoni, Athanasios Gouliamos.   

Abstract

INTRODUCTION: Embryonal rhabdomyosarcoma (RMS) of the uterine cervix is a rare and extremely malignant entity. Generally, embryonal RMS originating in the uterine cervix is usually diagnosed in adolescence. Before the introduction of effective adjuvant chemotherapy, the prognosis of these lesions was poor. We have treated a young woman suffering from this disease using a combination of surgery, chemotherapy and radiation therapy (RT) with excellent results. The medical community should keep in mind that embryonal RMS of the uterine cervix, despite its malignancy and rarity, can be cured if adequate treatment is given. CASE: A case of a young woman aged 20, presenting with vaginal bleeding, is reported. The histological examination revealed embryonal RMS of uterine cervix. The patient was treated with a combination of surgery, chemotherapy and RT. A review in the literature, which is also presented, shows that the combined treatment of embryonal RMS using surgery and multidrug chemotherapy has significantly improved survival.
CONCLUSION: Patients with favourable prognostic parameters, such as localised disease without deep myometrial invasion, single polyp and embryonal histologic subtype, can effectively be treated by surgery. Patients with unfavourable prognostic parameters seem to benefit from a multimodality approach including surgery, adjuvant chemotherapy and RT.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19531457     DOI: 10.1007/s12094-009-0376-0

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  11 in total

1.  Incidence of malignant tumors in U. S. children.

Authors:  J L Young; R W Miller
Journal:  J Pediatr       Date:  1975-02       Impact factor: 4.406

2.  Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.

Authors:  W M Crist; J R Anderson; J L Meza; C Fryer; R B Raney; F B Ruymann; J Breneman; S J Qualman; E Wiener; M Wharam; T Lobe; B Webber; H M Maurer; S S Donaldson
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

Review 3.  Sarcoma botryoides of the cervix: excision followed by adjuvant chemotherapy for preservation of reproductive function.

Authors:  A N Gordon; T W Montag
Journal:  Gynecol Oncol       Date:  1990-01       Impact factor: 5.482

4.  Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Studies I to III.

Authors:  S L Wolden; J R Anderson; W M Crist; J C Breneman; M D Wharam; E S Wiener; S J Qualman; S S Donaldson
Journal:  J Clin Oncol       Date:  1999-11       Impact factor: 44.544

5.  Rhabdomyosarcoma: the experience of the pediatric unit of Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine (NEMROCK) (from January 1992 to January 2001).

Authors:  Hisham H Abd El-Aal; Emmad E Habib; Mohamed M Mishrif
Journal:  J Egypt Natl Canc Inst       Date:  2006-03

6.  Rhabdomyosarcoma of the uterine cervix. Sarcoma botryoides.

Authors:  E Brand; J S Berek; R K Nieberg; N F Hacker
Journal:  Cancer       Date:  1987-10-01       Impact factor: 6.860

7.  Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84.

Authors:  F Flamant; C Rodary; A Rey; M T Praquin; D Sommelet; E Quintana; S Theobald; M Brunat-Mentigny; J Otten; P A Voûte; J L Habrand; H Martelli; A Barrett; M J Terrier-Lacombe; O Oberlin
Journal:  Eur J Cancer       Date:  1998-06       Impact factor: 9.162

Review 8.  Sarcoma botryoides of the uterine cervix in young women: a clinicopathological study of 13 cases.

Authors:  D A Daya; R E Scully
Journal:  Gynecol Oncol       Date:  1988-03       Impact factor: 5.482

9.  Radiation therapy for rhabdomyosarcoma: local failure risk for Clinical Group III patients on Intergroup Rhabdomyosarcoma Study II.

Authors:  M D Wharam; J J Hanfelt; M C Tefft; J Johnston; L G Ensign; J Breneman; S S Donaldson; C Fryer; E A Gehan; R B Raney; H M Maurer
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-07-01       Impact factor: 7.038

10.  Sarcomas of the vagina and uterus: the Intergroup Rhabdomyosarcoma Study.

Authors:  D M Hays; H Shimada; R B Raney; M Tefft; W Newton; W M Crist; W Lawrence; A Ragab; H M Maurer
Journal:  J Pediatr Surg       Date:  1985-12       Impact factor: 2.545

View more
  3 in total

1.  Embryonal rhabdomyosarcoma of the uterine cervix: a report of 14 cases and a discussion of its unusual clinicopathological associations.

Authors:  Louis P Dehner; Jason A Jarzembowski; D Ashley Hill
Journal:  Mod Pathol       Date:  2011-12-09       Impact factor: 7.842

2.  Sarcoma botryoides in an infant.

Authors:  S J van Sambeeck; A M C Mavinkurve-Groothuis; U Flucke; N Dors
Journal:  BMJ Case Rep       Date:  2014-12-17

3.  Causes and palliation of transfusion-associated vaginal bleeding in patients with metastatic cancer.

Authors:  Amie E Jackson; Elisabeth K Stephens; Aminah Jatoi
Journal:  Int J Gynecol Cancer       Date:  2014-01       Impact factor: 3.437

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.